EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GBA1 in Parkinson’s disease: past, present and future

Ziv Gan-Or iD

Brain · 18.09.2026

DOI: 10.1093/brain/awag322 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 18.09.2026. Verfasst von Ziv Gan-Or. Beteiligte Einrichtung: Department of Neurology and Neurosurgery, McGill University, Montreal, QC, H3A 2B4, Canada. Die Arbeit nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Galen and Hilary Weston Foundation, Hilary and Galen Weston Foundation, Silverstein Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GBA1 variants represent some of the most important genetic risk factors for Parkinson’s disease (PD), present in a substantial proportion of patients across populations. This review provides a comprehensive overview of the field, tracing the historical path from the first description of Gaucher disease (GD) in 1882 to the recognition of GBA1 as a key contributor to PD risk, highlighting major scientific and translational milestones along the way, summarizing current understanding of the biological mechanisms linking GBA1 to PD, including both loss-of-function and gain-of-function hypotheses, and discussing how reduced glucocerebrosidase (GCase) activity may lead to α-synuclein accumulation and neurodegeneration. Remaining gaps in knowledge, especially regarding downstream lipidomic effects and cell type-specific mechanisms, are emphasized as key priorities for future research. Clinical and translational advances are also examined, including the development of GCase-targeted therapies such as small molecules, chaperones, substrate reduction therapies and gene-based approaches. Outcomes from recent and ongoing clinical trials are discussed, highlighting both promising strategies and notable failures that inform our evolving understanding of disease biology. In addition, the heterogeneity of PD is addressed, together with the importance of stratifying patients based on genetic background. Finally, critical challenges and future directions are outlined, including the need for precision medicine approaches based on variant-specific mechanisms, improved biomarkers to define true GBA1-associated PD and optimized clinical trial design. Ultimately, coordinated, open-science efforts and large-scale collaborative frameworks are proposed to be essential in accelerating discovery and translating mechanistic insights into effective disease-modifying therapies.

Schlagwörter

Stichwörter der Autor:innen

GBA1Gaucher diseaseParkinson's diseaseglucocerebrosidase

Autor:innen und Institutionen

  • Department of Neurology and Neurosurgery, McGill University, Montreal, QC, H3A 2B4, Canada.
  • The Neuro (Montreal Neurological Institute-Hospital), Montreal, QC, H3A 2B4, Canada.
  • Department of Human Genetics, McGill University, Montreal, QC, H3A 1Y2, Canada.
  • Quantitative Life Sciences, McGill University, Montreal, QC, H3A 1E3, Canada.

ORCID-Profile: Ziv Gan-Or

Förderung

  • Galen and Hilary Weston Foundation
  • Hilary and Galen Weston Foundation
  • Silverstein Foundation
  • J. Sebastian van Berkom and Ghislaine Saucier

Zitieren

APA

Gan-Or, Z. (2026). GBA1 in Parkinson’s disease: past, present and future. Brain. https://doi.org/10.1093/brain/awag322

Vancouver

Gan-Or Z. GBA1 in Parkinson’s disease: past, present and future. Brain. 2026. doi:10.1093/brain/awag322

BibTeX
@article{GanOr2026,
  author = {Gan-Or, Ziv},
  title = {GBA1 in Parkinson’s disease: past, present and future},
  journal = {Brain},
  year = {2026},
  doi = {10.1093/brain/awag322}
}
Kostenlos starten →